期刊文献+

结直肠癌中HSF1、c-Jun、p-c-Jun及DPD的表达水平及临床意义 被引量:1

Expression level and clinical significance of HSF1,c-Jun,p-c-Jun,and DPD in colorectal cancer
下载PDF
导出
摘要 目的检测结直肠癌患者中热休克因子1(HSF1)、氨基末端激酶(c-Jun)、p-c-Jun及二氢嘧啶脱氢酶(DPD)的表达水平,并探讨其临床意义。方法收集南方医科大学南方医院2018年1月至2019年12月收治的114例结直肠癌患者的临床资料,检测结直肠癌组织及癌旁组织的HSF1、c-Jun、p-c-Jun及DPD表达情况,并对比HSF1、c-Jun、p-c-Jun及DPD阳性表达率,采用Log-rank检验分析不同HSF1、c-Jun、p-c-Jun及DPD阳性表达的结直肠癌患者预后情况,采用Spearman相关性分析法分析各指标之间的相关性。结果HSF1、c-Jun、p-c-Jun及DPD在结直肠癌组织中的阳性表达率分别为64.04%、61.40%、52.63%、58.77%,明显高于癌旁组织的23.68%、21.93%、14.04%、25.44%,差异均有统计学意义(P<0.05);Ⅲ+Ⅳ期、低分化、淋巴结转移阳性者HSF1、c-Jun、p-c-Jun及DPD阳性表达率,明显高于Ⅰ+Ⅱ期、中高分化、淋巴结转移阴性者,差异均有统计学意义(P<0.05);HSF1、c-Jun、p-c-Jun及DPD阳性者1年生存率分别为83.56%、82.86%、81.67%、83.58%,明显低于阴性者的97.56%、97.73%、97.30%、95.74%,差异均有统计学意义(P<0.05);结直肠癌患者HSF1、c-Jun、p-c-Jun及DPD之间的表达水平均呈正相关(P<0.05)。结论结直肠癌组织中HSF1、c-Jun、p-c-Jun及DPD的阳性表达率均高于癌旁组织,且与结直肠癌的临床分期、分化程度、淋巴结转移有关。 Objective To detect the expression levels of heat shock factor 1(HSF1),amino terminal kinase(c-Jun),p-c-Jun,and dihydropyrimidine dehydrogenase(DPD)in colorectal cancer patients,and to explore their clinical significance.Methods The clinical data of 114 patients with colorectal cancer admitted to Nanfang Hospital,Southern Medical University from January 2018 to December 2019 were collected,and the expressions of HSF1,c-Jun,p-c-Jun and DPD in colorectal cancer tissues and adjacent tissues were detected.Log rank test was used to analyze the prognosis of colorectal cancer patients with different expressions of HSF1,c-jun,p-c-jun and DPD.Spearman correlation analysis was used to analyze the correlation between the indicators.Results The positive expression rates of HSF1,c-Jun,p-c-Jun,and DPD in colorectal cancer tissues were 64.04%,61.40%,52.63%,and 58.77%,respectively,which were sig-nificantly higher than 23.68%,21.93%,14.04%,25.44%in adjacent tissues(P<0.05);the expression rates of HSF1,c-Jun,p-c-Jun,and DPD in patients with stageⅢ+Ⅳ,poorly differentiated and lymph node metastasis were significant-ly higher than those with stageⅠ+Ⅱ,moderately well differentiated and negative lymph node metastasis(P<0.05);the 1-year survival rates of HSF1,c-Jun,p-c-Jun and DPD positive patients were 83.56%,82.86%,81.67%,and 83.58%,which were significantly lower than 97.56%,97.73%,97.30%,95.74%of HSF1,c-jun,p-c-jun,and DPD negative pa-tients(P<0.05);the expression levels of HSF1,c-Jun,p-c-Jun,and DPD in colorectal cancer patients were positively cor-related(P<0.05).Conclusion The positive expression rates of HSF1,c-Jun,p-c-Jun,and DPD in colorectal cancer tis-sues are higher than those in adjacent tissues,which are related to the clinical stage,differentiation degree and lymph node metastasis of colorectal cancer.
作者 邓江 黎相照 DENG Jiang;LI Xiang-zhao(Department of Pathology,the Second People's Hospital of Longgang District of Shenzhen,Shenzhen 518112,Guangdong,CHINA;Department of Pathology,Nanfang Hospital,Southern Medical University,Guangzhou 510515,Guangdong,CHINA)
出处 《海南医学》 CAS 2021年第15期1926-1930,共5页 Hainan Medical Journal
关键词 结直肠癌 热休克因子1 氨基末端激酶 p-c-Jun 二氢嘧啶脱氢酶 Colorectal cancer Heat shock factor 1 Amino terminal kinase p-c-Jun Dihydropyrimidine dehy-drogenase
  • 相关文献

参考文献11

二级参考文献91

  • 1HuiCen,ShuZheng,Yong-MingFang,Xiao-PingTang,QiDong.Induction of HSF1 expression is associated with sporadic colorectal cancer[J].World Journal of Gastroenterology,2004,10(21):3122-3126. 被引量:14
  • 2贾莉,李建华,蔡剑平,郭健.汉族人群中二氢嘧啶脱氢酶基因多态性的初步研究[J].中日友好医院学报,2005,19(4):202-204. 被引量:13
  • 3Heggie GD, Sommadossi JP, Cross DS, et al. Clinical phar- macokinetics of 5-fluorouracil and its metabolites in plas- ma, urine, and bile[J]. Cancer Res, 1987, 47(8): 2203-2206.
  • 4van Kuilenburg AB, van Lenthe H, van Gennip AH. Activity of pyrimidine degradation enzymes in normal tissues[J]. Nu- cleosides Nucleotides Nucleic Acids, 2006, 25(9- 11): 1211- 1214.
  • 5Lu Z, Zhang R, Diasio RB. Dihydropyrimidine dehydroge- nase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified defi- cient patients, and clinical implication in 5-fluorouracil che- motherapy[J]. Cancer Res, 1993, 53(22): 5433-5438.
  • 6Takai S, Fernandez-Salguero P, Kimura S, et al. Assignment of the human dihydropyrimidine dehydrogenase gene (DPYD) to chromosome region lp22 by fluorescence in si- tu hybridization[J]. Genomics, 1994, 24(3): 613-614.
  • 7Wei X, Elizondo G, Sapone A, et al. Characterization of the human dihydropyrimidine dehydrogenase gene[J]. Genom- ics, 1998, 51(3): 391-400.
  • 8Dobritzsch D, Schneider G, Schnackerz KD, et al. Crystal structure of dihydropyrirnidine dehydrogenase, a major de- terminant of the pharmacokinetics of the anti-cancer drug 5- fluorouracil[J]. EMBO J, 2001,20(4): 650-660.
  • 9Tuchman M, Stoeckeler JS, Kiang DT, et al. Familial pyrim- idinemia and pyrimidinuria associated with severe fluoro- uracil toxicity[J]. N Engl J Med, 1985, 313(4): 245-249.
  • 10L6vy E, Piedbois P, Buyse M, et al. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of admin- istration schedule and prognostic factors[J]. J Clin Oncol, 1998, 16(11): 3537-3541.

共引文献91

同被引文献6

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部